Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 4/20 | 0.47 |
| ▸ | CTSS | P25774 | 4/20 | 0.47 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.42 |
| ▸ | F13A1 | P00488 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | TGM1 | P22735 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3318502 | 0.91 | SRD5A1 (0.55) | CCR1CTSLCTSSCTSKSRD5A1 | |
| SCHEMBL3322049 | 0.89 | CYP3A4 (0.49) | CCR1CTSLCTSSCTSKSRD5A1 | |
| SCHEMBL3323193 | 0.85 | CTSS (0.43) | CCR1CTSLCTSSCTSK | |
| SCHEMBL3320633 | 0.83 | CCR1 (0.55) | CCR1CTSLCTSSCTSKF13A1 | |
| SCHEMBL3321370 | 0.83 | TGM2 (0.45) | CCR1CTSLCTSKP2RX7TGM2 | |
| SCHEMBL6135874 | 0.81 | MEN1 (0.55) | CCR1 | |
| SCHEMBL3320206 | 0.80 | L3MBTL1 (0.46) | CTSLCTSSCTSKPREP | |
| SCHEMBL1648387 | 0.79 | SMN1; SMN2 (0.61) | — | |
| SCHEMBL13798752 | 0.78 | MEN1 (0.55) | CCR1CTSLCTSSCTSKPREP | |
| SCHEMBL3321981 | 0.78 | CCR1 (0.48) | CCR1CTSLCTSSCTSKPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125075-A1 | Antibacterial Agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2010-05-20 | — | — | US | disclosed |
| US-7186719-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2007-03-06 | — | — | US | disclosed |
| US-20050065095-A1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2005-03-24 | — | — | US | disclosed |
| US-6846825-B1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2005-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065095-A1 | Antibacterial agents | NQO2, DAO, Q6ZSR9 | CCR1 1395/4885CTSL 355/4885CTSS 760/4885 |
| US-20100125075-A1 | Antibacterial Agents | NQO2, DAO, Q6ZSR9 | CCR1 1421/4885CTSL 330/4885CTSS 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.